The U.S. Food and Drug Administration (FDA) has issued a warning to Novo Nordisk over its alleged failure to report adverse side effects, including death, in patients who took its GLP-1 medications. The FDA cited three deaths among patients using semaglutide, the active ingredient in several of the company's weight-loss medications, which it claimed were not properly investigated or reported. The company also violated procedures that required follow-ups in cases where death occurred, and failed to report any adverse reactions within the required 15-day period. The warning was issued in a March 5 letter, which the FDA dismissed as "inadequate" and gave Novo 15 days to address the issue.